2021年11月5日 · KMT2A partial tandem duplication (KMT2A -PTD), characterized by a large internal duplication spanning 6-8 exons, has been documented in adult AML with a prevalence …

KMT2A partial tandem duplication (PTD) involves intragenic duplications within the KMT2A gene and has been associated with acute myeloid leukemia (AML) and myelodysplastic syndrome …

2023年11月2日 · KMT2A -PTD (also called MLL -PTD, partial tandem duplication), a non-fusion gene rearrangement, also occurs and serves as an important biomarker for Menin-inhibitors. …

KMT2A partial tandem duplication (KMT2A -PTD) is an adverse risk factor in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), a potential therapeutic target, and an …

Partial tandem duplication (PTD) of the KMT2A (MLL) gene is detected in approximately 5-10% of cases of acute myeloid leukemia (AML) 1 – 5 and within cases showing normal karyotype, …

2022年7月26日 · KMT2A partial tandem duplication (KMT2A-PTD) is an adverse risk factor in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), a potential therapeutic …

In this study, we developed a targeted RNA-based next-generation sequencing panel, together with single primer enrichment and unique molecular identifiers, to identify KMT2A -PTD as well …

2023年11月2日 · KMT2A -PTD (also called MLL -PTD, partial tandem duplication), a non-fusion gene rearrangement, also occurs and serves as an important biomarker for Menin-inhibitors. …

2023年11月2日 · Based on our retrospective analysis, KMT2A -PTD mut are associated with reduced prognosis and survival in AML patients compared to WT pts. However, poor …

KMT2A PTD is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains KMT2A PTD and acute myeloid leukemia as …